8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Feb 3, 2017)

Filed February 3, 2017For Securities:PFE

Summary

Pfizer Inc. (PFE) announced on February 2, 2017, an accelerated share repurchase agreement with Citibank N.A. for $5 billion of its common stock. This significant buyback program underscores the company's commitment to returning capital to shareholders, aligning with a previously authorized share repurchase plan. Investors should note that a substantial portion of the shares will be delivered early, with the final settlement expected by the third quarter of 2017. The final share count or cash adjustment will be based on the volume-weighted average price of Pfizer's stock during the repurchase period, introducing a slight variable to the total value returned. This action indicates Pfizer's confidence in its stock valuation and its financial capacity to execute such a large-scale repurchase. While the immediate impact on share count is positive for existing shareholders through a reduction in outstanding shares, the variable nature of the final settlement could lead to adjustments based on market performance. The filing also references an accompanying press release for further details.

Key Highlights

  • 1Pfizer entered into a $5 billion accelerated share repurchase (ASR) agreement for its common stock.
  • 2The ASR agreement is with Citibank N.A.
  • 3Approximately 126 million shares are expected to be received by Pfizer on February 6, 2017.
  • 4The final settlement of the ASR is anticipated to occur during or prior to the third quarter of 2017.
  • 5The final number of shares repurchased or cash settlement will be based on the volume-weighted average price of Pfizer's common stock during the term of the transaction.
  • 6This repurchase is in accordance with Pfizer's previously announced share repurchase authorization.
  • 7A press release detailing the agreement was filed as an exhibit to the 8-K.

Frequently Asked Questions

An accelerated share repurchase agreement is a transaction where a company buys back its own stock from a bank or financial institution. The company typically receives a large portion of the shares upfront, with the final amount determined later based on market prices. It's a way for companies to quickly reduce outstanding shares and return capital to shareholders.

The final number of shares repurchased or any potential cash payment to or from Citibank will be determined by the volume-weighted average price (VWAP) of Pfizer's common stock during the term of the agreement. This means the exact number of shares Pfizer ultimately receives might be slightly more or less than initially estimated, depending on market fluctuations.

This large repurchase signals Pfizer's financial strength and its commitment to increasing shareholder value by reducing the number of outstanding shares. A reduction in share count can often lead to an increase in earnings per share (EPS) and may support the stock price.

Pfizer expects the final settlement of the accelerated share repurchase agreement to occur during or prior to the third quarter of 2017. While a significant portion of shares will be received on February 6, 2017, the full completion and final reconciliation will happen later in the year.